Aquestive Therapeutics Secures Two New U.S. Patents for Anaphylm™ Sublingual Epinephrine Film, Extending Protection Through 2037

Reuters

Oct 08

Aquestive <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures Two New U.S. Patents for Anaphylm™ Sublingual Epinephrine Film, Extending Protection Through 2037

Aquestive Therapeutics Inc. announced the issuance of two new U.S. patents for Anaphylm™, its novel sublingual film formulation of an epinephrine prodrug for the treatment of severe allergic reactions, including anaphylaxis. The newly granted patents, titled "Enhanced Delivery Epinephrine Compositions" and "Enhanced Delivery Epinephrine and Prodrug Compositions," cover proprietary formulations designed to enhance oral mucosal absorption of epinephrine. The patents extend protection for Anaphylm™ through at least 2037, reinforcing the company's intellectual property position as it advances the product toward potential regulatory approval. If approved, Anaphylm™ would become the first oral medication of its kind for emergency allergy treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541664-en) on October 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573947939"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573947939\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573947939?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573947939","market":"us","top_or_hot":-1,"title":"Aquestive Therapeutics Secures Two New U.S. Patents for Anaphylm™ Sublingual Epinephrine Film, Extending Protection Through 2037","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures Two New U.S. Patents for Anaphylm™ Sublingual Epinephrine Film, Extending Protection Through 2037\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AQST\">Aquestive Therapeutics Inc.</a> announced the issuance of two new U.S. patents for Anaphylm™, its novel sublingual film formulation of an epinephrine prodrug for the treatment of severe allergic reactions, including anaphylaxis. The newly granted patents, titled \"Enhanced Delivery Epinephrine Compositions\" and \"Enhanced Delivery Epinephrine and Prodrug Compositions,\" cover proprietary formulations designed to enhance oral mucosal absorption of epinephrine. The patents extend protection for Anaphylm™ through at least 2037, reinforcing the company's intellectual property position as it advances the product toward potential regulatory approval. If approved, Anaphylm™ would become the first oral medication of its kind for emergency allergy treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541664-en) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aquestive Therapeutics Secures Two New U.S. Patents for Anaphylm™ Sublingual Epinephrine Film, Extending Protection Through 2037</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAquestive Therapeutics Secures Two New U.S. Patents for Anaphylm™ Sublingual Epinephrine Film, Extending Protection Through 2037\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-08 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures Two New U.S. Patents for Anaphylm™ Sublingual Epinephrine Film, Extending Protection Through 2037\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AQST\">Aquestive Therapeutics Inc.</a> announced the issuance of two new U.S. patents for Anaphylm™, its novel sublingual film formulation of an epinephrine prodrug for the treatment of severe allergic reactions, including anaphylaxis. The newly granted patents, titled \"Enhanced Delivery Epinephrine Compositions\" and \"Enhanced Delivery Epinephrine and Prodrug Compositions,\" cover proprietary formulations designed to enhance oral mucosal absorption of epinephrine. The patents extend protection for Anaphylm™ through at least 2037, reinforcing the company's intellectual property position as it advances the product toward potential regulatory approval. If approved, Anaphylm™ would become the first oral medication of its kind for emergency allergy treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541664-en) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL3wHm0w:1","article_id":"2573947939","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573947939","pubTimestamp":1759921229,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aquestive Therapeutics Secures Two New U.S. Patents for Anaphylm Sublingual Epinephrine Film, Extending Protection Through 2037. Aquestive Therapeutics Inc. announced the issuance of two new U.S. patents for Anaphylm, its novel sublingual film formulation of an epinephrine prodrug for the treatment of severe allergic reactions, including anaphylaxis. The newly granted patents, titled \"Enhanced Delivery Epinephrine Compositions\" and \"Enhanced Delivery Epinephrine and Prodrug Compositions,\" cover proprietary formulations designed to enhance oral mucosal absorption of epinephrine. The patents extend protection for Anaphylm through at least 2037, reinforcing the company's intellectual property position as it advances the product toward potential regulatory approval. If approved, Anaphylm would become the first oral medication of its kind for emergency allergy treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4007":"制药","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","AQST":"Aquestive Therapeutics Inc.","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Aquestive Therapeutics获得Anaphylm的两项新美国专利™舌下肾上腺素膜，将保护延长至2037年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AQST":0.9,"NDAQ":0.9},"content_text":"Aquestive Therapeutics Secures Two New U.S. Patents for Anaphylm™ Sublingual Epinephrine Film, Extending Protection Through 2037\n    \n\nAquestive Therapeutics Inc. announced the issuance of two new U.S. patents for Anaphylm™, its novel sublingual film formulation of an epinephrine prodrug for the treatment of severe allergic reactions, including anaphylaxis. The newly granted patents, titled \"Enhanced Delivery Epinephrine Compositions\" and \"Enhanced Delivery Epinephrine and Prodrug Compositions,\" cover proprietary formulations designed to enhance oral mucosal absorption of epinephrine. The patents extend protection for Anaphylm™ through at least 2037, reinforcing the company's intellectual property position as it advances the product toward potential regulatory approval. If approved, Anaphylm™ would become the first oral medication of its kind for emergency allergy treatment.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541664-en) on October 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}